Cidara Therapeutics' ($CDTX) once-a-week antifungal therapy came through in the first of two Phase I trials, emboldening the company to press ahead with its lead therapy. The drug, CD101, is an intravenous treatment for invasive fungal infections including candidemia. In a single ascending-dose trial on 32 healthy volunteers, the drug was well-tolerated with no serious side effects, Cidara said, and demonstrated a pharmacokinetic profile consistent with preclinical studies. Now the company is waiting on results from a multiple ascending-dose study, slated to report out early next year, and blueprinting a Phase II trail in candidemia in the first half of 2016. More